Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.09+0.01 (+0.06%)
Close on Nov 13, 2026Market cap $3.96BP/E –Yield –
Relay Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Relay Therapeutics's enterprise value was $4.19B on Nov 11, 2026, against $1.28B a year earlier. Over the last 5 years it ranged from $313.11M to $4.19B, with a median of $1.28B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.19B | +206.0% |
| 2025 | Dec 31, 2025 | $1.37B | +155.8% |
| 2024 | Dec 31, 2024 | $535.22M | -55.6% |
| 2023 | Dec 29, 2023 | $1.20B | -16.9% |
| 2022 | Dec 30, 2022 | $1.45B | -44.7% |
| 2021 | Dec 31, 2021 | $2.62B | -17.4% |
| 2020 | Dec 31, 2020 | $3.17B | – |
See a number that looks wrong?